RxDoctor Payments Data

Stephen Rogers, MD

Family Medicine · Rensselaer, INNPI 1609879675

Payments from drug & device makers

$3,559in general payments, 2019–2025

Across 211 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$928
  • AbbVie$819
  • AstraZeneca$448
  • Otsuka America Pharmaceutical, Inc.$234
  • Braeburn Inc.$164
  • Amgen$103
  • plus $863 from 22 others

What the payments were for

  • Food & beverage$3,559100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,559 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$98,165
Medicare patients
134
Services billed
1,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban233$52,422
OzempicSemaglutide45$43,600
BrixadiBuprenorphine27$43,055
XareltoRivaroxaban171$39,453
FarxigaDapagliflozin Propanediol157$33,178
JardianceEmpagliflozin52$32,223
KerendiaFinerenone33$25,457
TradjentaLinagliptin32$15,923
Spiriva RespimatTiotropium Bromide25$14,923
LantusInsulin Glargine,hum.Rec.Anlog107$13,093
NuedextaDextromethorphan Hbr/Quinidine31$11,951
ArexvyRsvpref3 Antigen/As01e/Pf27$8,242
Breo ElliptaFluticasone/Vilanterol19$8,131
TrulicityDulaglutide18$7,866
Memantine Hcl418$7,785

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$19$63,070109 claims
Novo NordiskOzempic$85$43,60045 claims
Braeburn Inc.Brixadi$164$43,05527 claims
Johnson & JohnsonXarelto$25$39,453171 claims
AstraZenecaFarxiga$448$33,178157 claims
BayerKerendia$928$25,45733 claims
Lilly USA, LLCTrulicity$68$7,86618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Rensselaer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →